hypothalamic dysfunction hypothalamic damage pituitary insufficiency hypothalame schade hypothalame dysfunctie hypofyse-insufficientie
Conditions
Interventions
None listed
Sponsors
Academic Medical Center, Amsterdam
Meibergdreef 9
1105 AZ Amsterdam
Eligibility
Inclusion criteria
Inclusion criteria: 1. Having pituitary insufficiency and suspicion of hypothalamic damage OR having pituitary insufficiency without suspicion of hypothalamic damage OR (in case of controls) being healthy; 2. Age between 18-75 years old.
Exclusion criteria
Exclusion criteria: 1. Unwilling or unable to provide informed consent; 2. Serious neuropsychiatric problems; 3. Use of medication which interferes with serotonin metabolism (e.g. psychotropic medication like SSRIs or other antidepressants) and dopamin metabolism; 4. Life-time ecstasy, amphetamine or cocaine use; 5. Intravenous drug abuse; 6. Participation in another study associated with exposure to ionizinf radiation during the last 12 months; 7. Pregnancy; 8. Contra-indications for MRI.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in binding ratio (hypothalamus to occipital cortex/cerebellum) of the radioligand [123I]FP-CIT to serotonin transporters in the hypothalamus in subjects with hypopituitarism and clinical suspicion of hypothalamic dysfunction compared to subjects with pituitary insufficiency but no clinical suspicion of hypothalamic damage and healthy age- and gender-matched controls. | — |
Secondary
| Measure | Time frame |
|---|---|
| The optimal time-point to assess central serotonin transporter binding with FP-CIT SPECT after injection of the radiotracer. | — |
Contacts
Public ContactA.J.F. Borgers
Meibergdreef 9, Room F5-165
Outcome results
None listed